BEACON CRC shines spotlight on triplet, doublet regimens for BRAF V600E-mutated disease
10 Dec 2019
byJairia Dela Cruz
Use of the triplet regimen containing encorafenib, cetuximab and binimetinib, or a doublet regimen containing the first two, confers significant benefits for overall survival and response as compared with standard therapy in the treatment of metastatic colorectal cancer (CRC) harbouring the BRAF V600E mutation, according to the initial results of the phase III, open-label BEACON CRC trial.